Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Change in Receivables (2017 - 2024)

Avalo Therapeutics (AVTX) has disclosed Change in Receivables for 8 consecutive years, with -$387000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Change in Receivables rose 72.4% year-over-year to -$387000.0, compared with a TTM value of $475000.0 through Dec 2024, up 126.64%, and an annual FY2024 reading of $475000.0, up 126.64% over the prior year.
  • Change in Receivables was -$387000.0 for Q4 2024 at Avalo Therapeutics, down from $965000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $3.7 million in Q3 2020 and bottomed at -$3.5 million in Q4 2020.
  • Average Change in Receivables over 5 years is -$7950.0, with a median of -$51500.0 recorded in 2024.
  • The sharpest move saw Change in Receivables surged 1022.33% in 2020, then tumbled 340.71% in 2022.
  • Year by year, Change in Receivables stood at -$3.5 million in 2020, then soared by 136.0% to $1.3 million in 2021, then rose by 8.16% to $1.4 million in 2022, then crashed by 202.71% to -$1.4 million in 2023, then surged by 72.4% to -$387000.0 in 2024.
  • Business Quant data shows Change in Receivables for AVTX at -$387000.0 in Q4 2024, $965000.0 in Q3 2024, and -$2000.0 in Q2 2024.